Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label safety study of Jivi (BAY 94-9027) in children with severe hemophilia A
2023-504388-18-00Phase 3Completed
- Sponsor
- Bayer
- Start
- Sep 2022
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 7
01
Overview
Phase 3, open-label, single-arm trial of damoctocog alfa pegol in hemophilia A, sponsored by Bayer. Primary endpoint: AESI (hypersensitivity and loss of efficacy) associated with the first 4 exposure days leading to discontinuation. Started Sep 2022; status: completed.
02
Drugs
damoctocog alfa pegol
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2023-504388-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504388-18-00.